How to buy Aligos Therapeutics stock - 03 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aligos Therapeutics stock

Own Aligos Therapeutics stock in just a few minutes.

Updated . What changed?

Fact checked

Aligos Therapeutics, Inc is a biotechnology business based in the US. Aligos Therapeutics shares (ALGS) are listed on the NASDAQ and all prices are listed in US Dollars. Aligos Therapeutics employs 73 staff and has a market cap (total outstanding shares value) of USD$922 million.

How to buy shares in Aligos Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Aligos Therapeutics. Find the stock by name or ticker symbol: ALGS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aligos Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Aligos Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Aligos Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Aligos Therapeutics share price

Use our graph to track the performance of ALGS stocks over time.

Aligos Therapeutics shares at a glance

Information last updated 2021-03-03.
52-week rangeUSD$12.82 - USD$37.5099
50-day moving average USD$28.3494
200-day moving average USD$23.3985
Wall St. target priceUSD$34.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Aligos Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aligos Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aligos Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$922 million

TTM: trailing 12 months

Shorting Aligos Therapeutics shares

There are currently 1.4 million Aligos Therapeutics shares held short by investors – that's known as Aligos Therapeutics's "short interest". This figure is 4.2% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Aligos Therapeutics shares can be evaluated.

Aligos Therapeutics's "short interest ratio" (SIR)

Aligos Therapeutics's "short interest ratio" (SIR) is the quantity of Aligos Therapeutics shares currently shorted divided by the average quantity of Aligos Therapeutics shares traded daily (recently around 73683.855291577). Aligos Therapeutics's SIR currently stands at 18.52. In other words for every 100,000 Aligos Therapeutics shares traded daily on the market, roughly 18520 shares are currently held short.

To gain some more context, you can compare Aligos Therapeutics's short interest ratio against those of similar companies.

However Aligos Therapeutics's short interest can also be evaluated against the total number of Aligos Therapeutics shares, or, against the total number of tradable Aligos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aligos Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aligos Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0391% of the tradable shares (for every 100,000 tradable Aligos Therapeutics shares, roughly 39 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Aligos Therapeutics.

Find out more about how you can short Aligos Therapeutics stock.

Aligos Therapeutics share dividends

We're not expecting Aligos Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Aligos Therapeutics overview

Aligos Therapeutics, Inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB). The company is also developing ALG-000184, a capsid assembly modulator to treat CHB; ALG-020572, a oligonucleotide for the treatment of CHB; ALG-125097, an siRNA drug candidate to treat CHB; and ALG-055009, a small molecule THR-ß agonist for the treatment of non-alcoholic steatohepatitis. Aligos Therapeutics, Inc. was founded in 2018 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site